Nootropics & Neuroprotection
CAS
12656-61-0
Molecular Weight
0
Da
Cerebrolysin is a porcine brain-derived peptide mixture developed in Austria and widely used in Europe and Asia for stroke rehabilitation, traumatic brain injury, and Alzheimer's disease. It contains a range of low-molecular-weight peptides that cross the blood-brain barrier and are proposed to mimic neurotrophic factors. Multiple RCTs exist, primarily in Eastern Europe and China. Results are mixed, positive in several stroke recovery trials, less consistent in Alzheimer's, and independent Western replication is limited. The evidence base is real but geographically concentrated.
Injectable · IV
Intranasal Suitable
No
Approved in 30+ countries. Not FDA approved. Not available for prescription in the US or UK.
We break down one compound like this every week.
Subscribe free to The Honest Dose, and get the RQS Reference, every compound in the catalog scored on one page, as a welcome gift.
Cerebrolysin has a substantial and longstanding following in the nootropics community, particularly among users focused on neuroprotection and recovery from brain injury. It is considered one of the more "serious" nootropics, less accessible than oral compounds, harder to source in the US, and requiring injection. Community discussion frequently references the Eastern European clinical tradition and debates whether the geographic concentration of evidence reflects genuine regional science capacity differences or publication bias. Experienced users report meaningful cognitive effects, particularly after courses of 10+ days. The injection requirement and grey-market sourcing keeps overall community volume lower than oral nootropics.
Cerebrolysin is a standardized injectable mixture derived from enzymatic breakdown of porcine brain proteins. The final product is a combination of low-molecular-weight peptide fragments (below 10 kDa) and free amino acids in physiological saline. Approximately 25% of the mixture by weight is biologically active peptide fractions. It is not a single defined compound but a complex mixture, this creates manufacturing consistency challenges and complicates direct comparison between study preparations. It is manufactured by EVER Neuro Pharma (Austria) and approved in over 30 countries, though not the US or UK.
Cerebrolysin's peptide fractions are proposed to act through multiple neurotrophic pathways. In vitro and animal data suggest effects on BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and GDNF (glial cell line-derived neurotrophic factor) signaling. Additional proposed mechanisms include reduction of apoptosis in neurons, anti-inflammatory effects in the CNS, and inhibition of amyloid precursor protein processing relevant to Alzheimer's pathology. The mixture format means no single mechanism dominates, it is understood as a multimodal neuroprotective intervention.
Cerebrolysin is approved and used clinically in 30+ countries for acute ischemic stroke rehabilitation, traumatic brain injury recovery, and Alzheimer's disease. In the nootropics community, it is used off-label for cognitive enhancement, neuroprotection, and post-injury brain recovery. The strongest evidence base is in acute stroke, the CASTA and CARS trials are the most cited. Alzheimer's evidence is less consistent across trials. Cognitive enhancement in healthy adults lacks dedicated RCT evidence.
The most commonly reported adverse effects are injection site reactions, mild agitation, and gastrointestinal discomfort. Cerebrolysin is administered intravenously or intramuscularly, not orally, which carries procedural risks if not administered in clinical settings. As a biological mixture derived from porcine brain, theoretical biosafety concerns (prion transmission) have been raised, though no confirmed cases exist and manufacturing processes include precautions. Allergic reactions are possible. Self-administration outside clinical supervision is a meaningful risk vector.
Cerebrolysin is produced as a sterile injectable solution (5ml and 10ml ampoules) for intravenous or intramuscular administration. Oral bioavailability is essentially zero, the peptide fractions are degraded in the GI tract. It is not suitable for subcutaneous injection. In clinical trial settings it is typically administered as slow IV infusions over 20–60 days. It is not FDA approved and therefore cannot be legally prescribed in the US. Research-grade vials circulate in the grey market, but IV self-administration carries significant safety risks.
Cerebrolysin is a registered pharmaceutical in more than 30 countries including Austria, Germany, China, Russia, and most of Eastern Europe and Asia. It is manufactured under European GMP standards. The FDA has not approved it for any indication in the US, it has been reviewed but remains outside the approved drug formulary. It is not on the FDA 503A bulk compounding list. In the UK, it is not MHRA approved. Despite its long clinical history internationally, regulatory asymmetry between Eastern Europe/Asia and Western regulatory bodies persists.
Enjoyed this profile? Get one compound broken down in depth every week in The Honest Dose.
Last Reviewed